Literature DB >> 28706361

Opportunistic Salpingectomy as an Ovarian Cancer Primary Prevention Strategy.

Geetha Balsarkar1.   

Abstract

Ovarian cancer is the most lethal form of all gynecologic malignancies. The presenting clinical symptoms of ovarian cancer are very vague and often appear late in the course of disease. Hence, most patients are diagnosed at later stages. At present, there is no effective screening of ovarian cancer. Primary prevention could be considered a strategy to decrease the mortality from ovarian cancer, not only in women at high risk but also in those at low risk. Most "ovarian cancers," and more specifically the high-grade serous carcinoma (HGSC) subtype of ovarian cancer, actually could originate in the fallopian tube. Women who have known BRCA1 or BRCA2 germline mutations should be counseled regarding bilateral salpingo-oophorectomy, immediately after completion of childbearing, as the best strategy for reducing their risk of developing ovarian cancer. If the patient is reluctant, they should be counseled regarding risk-reducing salpingectomy when childbearing is complete followed by oophorectomy in the future. For women at average risk of ovarian cancer, risk-reducing salpingectomy should also be discussed and considered with patients at the time of any abdominal or pelvic surgery, hysterectomy or tubal ligation.

Entities:  

Keywords:  Bilateral salpingo-oophorectomy; Fallopian tube origin; Ovarian cancer; Risk reduction; Screening for cancer

Year:  2017        PMID: 28706361      PMCID: PMC5491423          DOI: 10.1007/s13224-017-0998-z

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  8 in total

1.  The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory.

Authors:  Robert J Kurman; Ie-Ming Shih
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

2.  Ovarian cancer risk after salpingectomy: a nationwide population-based study.

Authors:  Henrik Falconer; Li Yin; Henrik Grönberg; Daniel Altman
Journal:  J Natl Cancer Inst       Date:  2015-01-27       Impact factor: 13.506

3.  Fallopian Tube Ligation or Salpingectomy as Means for Reducing Risk of Ovarian Cancer.

Authors:  J Brian Szender; Shashikant B Lele
Journal:  AMA J Ethics       Date:  2015-09-01

4.  Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?

Authors:  Mark H Greene; Phuong L Mai; Peter E Schwartz
Journal:  Am J Obstet Gynecol       Date:  2010-07-08       Impact factor: 8.661

Review 5.  Prophylactic salpingectomy and prophylactic salpingoophorectomy for adnexal high-grade serous epithelial carcinoma: A reappraisal.

Authors:  M Reyes Oliver Perez; Javier Magriñá; Alvaro Tejerizo García; Jesus Salvador Jiménez Lopez
Journal:  Surg Oncol       Date:  2015-10-08       Impact factor: 3.279

Review 6.  Why have ovarian cancer mortality rates declined? Part I. Incidence.

Authors:  Victoria Sopik; Javaid Iqbal; Barry Rosen; Steven A Narod
Journal:  Gynecol Oncol       Date:  2015-06-14       Impact factor: 5.482

Review 7.  The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.

Authors:  Clare J Reade; Ruaidhrí M McVey; Alicia A Tone; Sarah J Finlayson; Jessica N McAlpine; Michael Fung-Kee-Fung; Sarah E Ferguson
Journal:  J Obstet Gynaecol Can       Date:  2014-02

Review 8.  Opportunistic salpingectomy for ovarian cancer prevention.

Authors:  Gillian E Hanley; Jessica N McAlpine; Janice S Kwon; Gillian Mitchell
Journal:  Gynecol Oncol Res Pract       Date:  2015-09-17
  8 in total
  2 in total

1.  Hysterectomy with opportunistic salpingectomy versus hysterectomy alone.

Authors:  Laura A M van Lieshout; Miranda P Steenbeek; Joanne A De Hullu; M Caroline Vos; Saskia Houterman; Jack Wilkinson; Jurgen Mj Piek
Journal:  Cochrane Database Syst Rev       Date:  2019-08-28

2.  Ovarian cancer: Pathogenesis and current recommendations for prophylactic surgery

Authors:  I Nyoman Gede Budiana; Michelle Angelina; Tjokorda Gede Astawa Pemayun
Journal:  J Turk Ger Gynecol Assoc       Date:  2018-10-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.